Ibrahim, Myla M.
HRN: 28-87-50 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/16/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
04/16/2024
04/22/2024
IV
300mg
Q12
UTI
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes